Chiltern explained that Vigiun, which has been operating since 1999, is a specialist in conducting Phase I to IV trials, providing management, staffing and patient recruitment services to drug industry sponsors.
The UK firm highlighted Sao Paulo-based Vigiun’s track record in conducting trials of drugs for cancer, respiratory conditions and infectious disease as a key motivation for the acquisition.
Chiltern also said that Brazil’s 192m residents provide a vast pool from which to recruit trial subjects and added that Latin America is rich with experienced investigators and is known for high quality data and excellent patient retention in clinical trials.
John Vann, executive VP of Chiltern’s South American operations, said that: “The acquisition of Vigiun enhances Chiltern's growing presence in Latin America, which was established nearly a year ago when we began operations in Argentina under the leadership of Oscar Podesta, our General Manager for Latin America.”
Vann added that the expertise and experience of the two Vigiun founders, Eduardo Forleo and Elisa Halker who stay on under the deal, strengthens Chiltern's standing and ability to expand in the region.
These thoughts were echoed by Chiltern CEO Glenn Kerkhof who said: "Vigiun is an ideal complement to our existing Latin American operations and Chiltern's presence in 27 other countries as we serve the pharmaceutical and biotech industries globally."
Eduardo Forleo, who will manage operations in the country, said that: “Our business has grown to the point that it makes sense to join forces with a global CRO whose mission and values align with ours."